Dendreon Corp fka DNDNQ

[bioshortsqueezer]

Panel opinion on satraplatin at least shows ODAC consistency...

consistent in moving back the goalposts even after the ball has left the ground. Perhaps their rejection of Provenge is forcing them to hold to a hard line on satraplatin, or has managed to scare reasonable compassionate doctors into hoeing a statistical hard line. At least DNDN is not alone. Perhaps this will motivate biotech CEOs to back a lobbying effort with real staying power, like PhRMA does for big pharma. At this moment the biggest threat to them is the FDA, not each other. Genentech is an exception; not only are they secure for now with their approved drugs, but they will always have a shelter waiting for them in the wings of corporate parent Roche if the FDA storm comes their way.